Table 1.
Clinical studies investigating immunotherapy in adrenocortical carcinoma (ACC).
| Drug | Target | Clinical Trials.Gov Identifier | Study Phase | Status |
|---|---|---|---|---|
| Pembrolizumab | anti-PD-1 antibody |
NCT02673333 NCT02721732 |
II II |
Active, not recruiting Recruiting |
| Combination pembrolizumab and relacorilant | anti-PD-1 antibody and antagonist of the glucocorticoid receptor | NCT04373265 | I | Not yet recruiting |
| Nivolumab | anti-PD-1 antibody | NCT02720484 | II | Terminated |
| Combination nivolumab and ipilimumab | anti-PD-1 and anti-CTLA-4 antibody |
NCT02834013 NCT03333616 |
II II |
Recruiting Recruiting |